Press release

Care – the new name for high-performance plastics in medical technology

March 13, 2012

The new Care Product Line from Evonik Industries includes a wide range of high-performance polymers utilized in a variety of medical applications. The biocompatibility of our VESTAMID® Care and TROGAMID® Care Product Lines has been proven in comprehensive tests by independent testing institutes, and our materials meet USP Class VI requirements.

We offer a range of customized product solutions depending on the technical requirements for the medical device, whether flexible or rigid, transparent or translucent. For example, Care products are used in a variety of medical applications, such as in catheters for vascular treatment, in surgical instruments, or as selector valves for infusion equipment.

"When designing our Care products, we work closely with our customers to offer custom solutions as well as to pick up on and play out trends in the medical industry as they occur," says Christiane Röhnke, Medical Devices Business Manager.

Thanks to decades of experience, Evonik is one of the leaders in polymer design technology. Evonik assists its customers throughout the product development cycle—from material development to the manufacturing of the finished product.

Downloads

Linked Files

One of many application areas: Hearing aids

One of many application areas: Hearing aids

Download
Contact

Thomas Lange

Communications High Performance Polymers

  • 版权所有

    Evonik, the creative industrial group from Germany, is one of the world leaders
    in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
    Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.

  • In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.